Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in ...

FDA lifts clinical hold following review of Company’s Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests ...